Tin tức & Cập nhật
Xem bài viết Nội tiết
Xem
Pioglitazone–SGLT2 inhibitor combo delivers for primary CV prevention in diabetes
Combination treatment with pioglitazone plus a sodium-glucose co-transporter 2 (SGLT2) inhibitor helps reduce the risk of developing major adverse cardiovascular events (MACE) and heart failure in individuals with type 2 diabetes mellitus (T2DM) who have no history of cardiovascular disease (CV), as reported in a study.
Pioglitazone–SGLT2 inhibitor combo delivers for primary CV prevention in diabetes
09 Jun 2023
T2DM: SGLT2 inhibitors associated with lower rates of ICU admission and all-cause mortality
A retrospective observational study of nearly 28,000 patients with type 2 diabetes mellitus (T2DM) in Hong Kong finds that use of sodium-glucose cotransporter 2 (SGLT2) inhibitors is independently associated with lower rates of ICU admission and all-cause mortality across various disease categories.
T2DM: SGLT2 inhibitors associated with lower rates of ICU admission and all-cause mortality
07 Jun 2023
Electroporation a promising way to end insulin dependency in T2D
A novel endoscopic electroporation procedure, when combined with semaglutide, can eliminate the need for insulin injections for individuals with type 2 diabetes (T2D), as shown in the results of the first-in-human EMINENT study.
Electroporation a promising way to end insulin dependency in T2D
05 Jun 2023
What is the best predictor of glucose metabolism deterioration after bariatric surgery?
Weight regain measured as percentage of maximum weight lost (%MWL) appears to be a better predictor of postoperative glucose metabolism deterioration within 3 years than other quantifiers in patients with obesity and type 2 diabetes mellitus (T2DM) who underwent bariatric surgery, according to a China study. Of note, the optimal cutoff point is 20 percent MWL.
